As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications. On May 18, 2021, Québec announced that, subject to exceptions, patients who use a reference biologic for which one or more biosimilars are available will have to switch, under the supervision of their doctor, to a biosimilar drug by April 12, 2022. According to the announcement, this shift will result in annual savings of over $100 million dollars. Québec’s website on biosimilar drugs includes a section on the current situation regarding reimbursement.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Minister of Health announces new bilateral agreements with provinces for rare disease drugs
Canada’s first-ever National Strategy for Drugs for Rare Diseases includes up to $1.4 billion in funding for provinces and territories, to be negotiated through bilateral agreements.Read More -
Government of Canada announces first pharmacare agreements
The Minister of Health recently announced the first of these bilateral agreements with Manitoba ($219 million over four years), British Columbia ($670 million over four years) and Prince Edward Island...Read More -
PMPRB announces Anie Perrault as acting Chairperson and releases latest expenditure report on private drug plan costs and utilization
On March 6, 2025, the Patented Medicine Prices Review Board announced that Thomas Digby stepped down from his role as Chairperson of the PMPRB. Vice-Chairperson Anie Perrault is now serving as acting ...Read More